References The Lancet (2021) Onceweekly cagrilintide for weight management: phase 2 dosefinding trial (Lau et al.) Int J Mol Sci (2024) Amylin, another important neuroendocrine hormone for treatment of diabesity PMC (2022) Mediators of amylin action in metabolic control The Lancet (2021) Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg dose over 26 weeks N Engl J Med (2025) REDEFINE 1: Coadministered cagrilintide and semaglutide in adults with overweight or obesity The Lancet (2021) Cagrilintide + semaglutide phase 1b trial: safety, tolerability, pharmacokinetics (Enebo et al.) J Med Chem (2021) Development of cagrilintide: a longacting amylin analogue Brain Res Rev (2005) Pancreatic amylin as a centrally acting satiating hormone PMC (2006) Pancreatic signals controlling food intake: insulin, glucagon, and amylin PMC (2016) Amylinmediated control of glycemia, energy balance, and cognition PMC (2024) Clinical pharmacokinetics of semaglutide: systematic review (includes cagrilintide PK data) N Engl J Med (2025) REDEFINE 2: Cagrilintidesemaglutide in adults with overweight/obesity and type 2 diabetes CDC Vaccine administration: subcutaneous injection technique and site guidance CDC (PDF) You Call the Shots: subcutaneous injection diagram and best practices Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
For one, it can cause tiredness and can interfere with ones balance and motor function
Grootschalig menselijk onderzoek ontbreekt en de langetermijneffecten zijn onbekend, met mogelijke bijwerkingen zoals misselijkheid en irritatie
To simulate the impact of the proposed Overall Hospital Quality Star Rating methodology, we used the July 2024 refresh of the Overall Hospital Quality Star Rating (the most recent publicly released results as of the writing of the proposal) to describe the overall distribution and reclassification of the Overall Hospital Quality Star Rating across different types of hospitals
On the safety side, the Cosmetic Ingredient Review Expert Panel has concluded this ingredient to be safe as used in current cosmetic practices + concentrations
The study compared the effects of 5% m 6 A-circRNA and 100% -mRNA encoding human erythropoietin (hEpo)
